Liquidia Corporation
Liquidia Corporation (LQDA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · LQDA · as of Jun 8, 2026
Key Statistics
Explore Liquidia Corporation Data
lqda stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 85.7%
The LQDA analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $68.00, representing +4.99% upside from the current price of $64.77.
Competitors & Peers
lqda competitorsLQDA
AGIO
COGT
DNLI
ETNB
GLPGStock Performance
Full HistoryAbout Liquidia Corporation
Liquidia Corporation a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an…
what is liquidia corporation · lqda stock overview · liquidia corporation company profile · who is liquidia corporation ceo · lqda NASDAQ · liquidia corporation headquarters · liquidia corporation business segments
About Stock Overview & Key Data
Liquidia Corporation (LQDA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 26, 2018. As of the latest trading session, LQDA stock price is $64.77, with a market capitalization of $5.8B. The stock has returned +259.43% over the past 12 months and +87.79% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Liquidia Corporation stock is Buy, with an average 12-month price target of $68.00. In fiscal year 2025, Liquidia Corporation reported revenue of $158.3M and net income of -$68.9M. For detailed data — including Liquidia Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Liquidia Corporation (LQDA) stock price is $64.77. The stock is traded on NASDAQ under the ticker symbol LQDA. The 52-week range is $11.85 – $66.54.